Retatrutide is an experimental weight loss and diabetes drug developed by Eli Lilly. It's a triple hormone receptor agonist, meaning it activates GLP-1, GIP, and glucagon receptors. These hormones help regulate blood sugar, appetite, and metabolism. Early clinical trials have shown significant weight loss results, even greater than current GLP-1 drugs like semaglutide (found in Ozempic and Wegovy).